Clinical trial recruitment is often treated as a sequence of separate tasks: activate the site, approve campaign materials, find potential participants, screen, and randomise. In practice, it is one connected flow. Information (site readiness, approved materials, referrals and eligibility evidence) gates the physical journey of a person through screening and randomisation.
Value Stream Mapping (VSM) makes that flow visible. It shows the work, handoffs, queues and rework from end to end, helping teams distinguish time spent advancing a participant from time spent waiting. The aim is not to bypass safeguards or enrol unsuitable participants. It is to remove avoidable delay while protecting participant rights, data quality and protocol compliance.
Set a useful boundary: activation to first patient randomised
For this worked example, the value stream begins when site activation paperwork is complete and ends when the first patient is randomised at that site. The single-site loop makes ownership and waiting easier to see; repeated across sites, these loops shape the overall trial timeline.
The figures below are illustrative assumptions for a hypothetical Phase III site, not industry benchmarks. Actual times vary by protocol, site, country, ethics review and local requirements. Here, the recruitment campaign launches 21 days after activation, including a 12-day marketing-material approval loop. Chart reviews run in parallel with that approval work, so their seven-day batch interval is not added again to the critical path.
Current state: 58 days from activation to randomisation
The site needs one randomised patient every six days to meet its enrollment target. That demand pace is the site’s takt time. The current process takes 58 days to reach the first randomised patient, while ongoing queues also threaten the required recruitment cadence.
| Current-state step | Process time (PT) | Lead time (LT) / queue | What the map reveals |
|---|---|---|---|
| Activation paperwork complete → campaign launch | 0.50 hr | 21 days | Marketing-material approval loop takes 12 days |
| Chart pre-screening | 0.25 hr per chart; 12 charts per weekly session | Up to 7 days to next batch | 34 pre-screened patients waiting between steps |
| Eligibility pre-screen call | 0.42 hr (25 min) | 1 day | Manual coordination before the call |
| Consent appointment and visit | 1.00 hr | 9 days to appointment | Potential participants wait for an available slot |
| Screening appointment and visit | 1.25 hr | 14 days to appointment | 9 consented patients awaiting screening |
| Lab draw and report | 0.25 hr | 5 days | Results wait in the lab handoff |
| Eligibility confirmation committee | 0.25 hr | 7 days average; up to 14 | Primary bottleneck: fortnightly review cadence |
| Randomisation entry | 0.18 hr | 1 day after confirmation | Final administrative handoff |
The first-patient timeline is 21 + 1 + 9 + 14 + 5 + 7 + 1 = 58 calendar days. The weekly chart-review cycle occurs in parallel with campaign approval in this example; it is still a significant queue for other candidates. Allocated touch time totals 4.1 hours per patient.
Process Cycle Efficiency (PCE) compares value-adding process time with total lead time, using the same units. Converting 58 calendar days to 1,392 hours gives 4.1 ÷ 1,392 = 0.3% PCE. This is a reminder that most elapsed time is queue time, not a judgement about the importance of clinical work.
The fortnightly committee is the bottleneck because a patient whose results arrive just after a meeting may wait nearly two weeks for a decision. That makes committee cadence, alongside consent and screening capacity, a priority for the future state.
Find the eight wastes in the recruitment flow
The Lean DOWNTIME lens helps teams identify friction without losing sight of participant protection:
- Waiting: Participants wait between consent and screening; lab samples wait for reports.
- Defects: Missed or misread chart information can lead to avoidable screen failures and rework.
- Inventory: The pre-screened pool ages while 34 candidates await the next step.
- Transportation: Participants may travel for separate visits when protocol and site procedures could permit a combined visit.
- Motion: Coordinators spend time chasing material approvals and updates.
- Overprocessing: Eligibility is checked repeatedly at pre-screen and screening without a clear division of purpose.
- Non-utilised talent: Skilled coordinators maintain manual eligibility tables instead of focusing on clinical coordination and participant questions.
- Overproduction: More patients are consented than available screening slots can accommodate, creating a queue of nine.
These are prompts for investigation, not automatic instructions to remove a step. For instance, eligibility checks can be streamlined, but protocol-required confirmation remains essential.
Build a safer, faster future state
A practical future-state map connects approval, participant flow and decision-making while retaining appropriate oversight:
- Run a weekly eligibility committee with a rolling agenda. Review complete cases as they become ready rather than holding them for a fixed fortnightly meeting.
- Combine consent and screening visits where the protocol and approved procedures allow. Confirm appointment capacity before consenting candidates into a queue.
- Use e-consent and remote pre-screening calls where appropriate. Provide accessible alternatives and ensure the consent process remains informed, voluntary and properly documented.
- Set a lab turnaround service-level agreement (SLA) and level courier pickups to reduce sample waiting.
- Replace weekly chart-review batches with continuous pre-screening, following approved privacy, access and site procedures.
- Parallel-track campaign approval with activation so approved materials are ready for launch without delaying other activation work.
Under this illustrative design, the first patient is randomised in 31 days. Assume improved coordination reduces allocated process time to 3.4 hours, while queues shrink as shown below. At the same PCE definition, 3.4 hours divided by 744 hours (31 calendar days) is approximately 0.5%.
A 5.5% PCE would not reconcile with 3.4 hours of process time and a 31-day lead time: it would require about 41 hours of value-adding time. Teams should calculate PCE from their measured, consistently defined data rather than report an attractive but incompatible figure.
| Measure | Current state | Future-state illustration |
|---|---|---|
| Activation to first randomised patient | 58 days | 31 days |
| Allocated process time | 4.1 hours | 3.4 hours |
| PCE (same-unit calculation) | 0.3% | 0.5% |
| Pre-screen queue WIP | 34 | 12 |
| Consented, awaiting screening | 9 | 3 |
| Awaiting lab report | Illustrative baseline: 6 | 2 |
| Awaiting eligibility decision | Illustrative baseline: 8 | 3 |
| Screen-failure rate | Illustrative baseline: 35% | Illustrative target: 30% |
| Site enrollment takt | 1 patient every 6 days | 1 patient every 6 days |
The screen-failure figures are scenario assumptions, not predicted results. Track the actual rate and reasons by criterion; do not change eligibility decisions to improve a metric. Likewise, 31 days to the first randomisation is not the same as meeting a six-day takt. It is an earlier start; the site still needs to sustain the required patient flow thereafter.
Sequence kaizen over 90 days
Days 1–30: Stabilise the queues
- Start weekly committee reviews with a rolling case agenda.
- Move from weekly chart-review batches to continuous pre-screening.
- Establish baseline definitions and track queue age, WIP and decision turnaround.
Days 31–60: Improve appointment and lab flow
- Pilot combined consent-screening visits where protocol, ethics approval and site procedures permit.
- Agree and monitor the lab turnaround SLA and courier schedule.
- Review screening-slot capacity against the number of consented participants.
Days 61–90: Reduce approval delay and support scale
- Roll out e-consent where approved, accessible and suitable for participants.
- Parallel-track campaign-material approval with activation tasks.
- Compare results by site and review screen-failure reasons, participant experience and compliance measures before standardising.
ICH E6(R3) Good Clinical Practice emphasises participant protection, informed consent, quality built into trial design and operationally feasible processes. Any process change affecting recruitment materials, consent, privacy, eligibility or protocol procedures must follow applicable approvals and requirements. For background, see the FDA’s E6(R3) GCP guidance. A practical example of mapping recruitment work and clarifying responsibilities is available from SOCRA’s workflow-mapping case.
Turn the map into measurable improvement
A VSM is valuable when teams use it to test the causes of delay, not merely document them. Start with timestamps and WIP at each queue, agree on the definition of process time and lead time, then review the future state against both flow and quality measures. For more on the method, use our Process Cycle Efficiency Calculator.
Build the skills to lead improvements like this. Explore CSSC-accredited Lean Six Sigma training from White Belt to Master Black Belt: self-paced online learning, practical application and real DMAIC case studies and simulations. Choose a certification pathway and start applying improvement methods to your work.
Kaizen. Kai-Care. Kai-Done. Lean Six Sigma.
